SecBot SecBot
Biotech Drug Report Generated Aug 2, 2026

Zeposia

BMY·BRISTOL MYERS SQUIBB CO
NEUTRAL
Drug Impact Rating3/10
Trial phase
Approved (US approval recorded 2020-03-25); no active Phase 2/3 industry-sponsored trials for ozanimod/Zeposia in SecBot
Time to market
Already on the market, approved (US FDA approval recorded 2020-03-25 in SecBot's local catalyst data); commercialized by Bristol Myers Squibb.
Why 3/10
Zeposia is already approved and marketed, and no Zeposia-specific PDUFA, pivotal readout, or label-expansion catalyst appears in local FDA/event data for the next ~12 months, so there is no dated binary to trade, and at BMY scale this one product is a small part of a huge portfolio.
Actionable Insight NEUTRAL

There is no near-term Zeposia-specific event to trade, the drug's binary (approval) already passed in 2020, and BMY's scheduled FDA catalysts in local data are other assets (iberdomide PDUFA 2026-08-17; Reblozyl PDUFA 2027-03-11; mezigdomide PDUFA 2027-05-13). Watch BMY's quarterly filings (10-Q/8-K) for the Zeposia sales line if you want to track this product specifically; the stock is more likely to move on BMY's portfolio-wide results and those other catalysts than on Zeposia alone.

Price Chart

Loading chart...

Executive Summary

Zeposia (generic name ozanimod) is an oral, marketed Bristol Myers Squibb drug, SecBot's local FDA-catalyst records log a Zeposia FDA-approval event dated 2020-03-25 with a positive 1-day (+6.11%) and 5-day (+10.46%) stock reaction around it, and the drug is listed among BMY's products in the company's Q2 2026 earnings 8-K analysis. BMY trades near $65.31 (2026-07-31 close), with analyst consensus "hold", a mean price target of $64.91, and short interest of ~44.9M shares (~2.2% of estimated shares outstanding) at the 2026-07-15 settlement. Net read: a real but modest commercial asset inside a mega-cap, with no near-term binary of its own, hence neutral.

How It Works

Zeposia (ozanimod) is an oral drug from the class of sphingosine 1-phosphate (S1P) receptor modulators, it keeps certain immune cells from escaping lymph nodes, reducing the inflammatory immune traffic that drives autoimmune disease.

Trial Status

SecBot's local FDA-catalyst log shows a Zeposia FDA-approval event dated 2020-03-25 (BMY stock +6.11% over 1 day and +10.46% over 5 days around it in the local outcomes record). No Zeposia-specific regulatory filings, label-expansion submissions, or scheduled trial readouts appear in local FDA catalyst/event data for the trailing year or the next 12 months. Zeposia is named among BMY's marketed products in the company's Q2 2026 earnings 8-K filing analysis.

The Two-Sided Case

▲ Bull Case3
Zeposia is already FDA-approved and commercialized, so it contributes revenue with no regulatory-approval risk remaining.
The market reacted positively to Zeposia milestones historically: the recorded approval catalyst coincided with a +6.11% 1-day and +10.46% 5-day move in BMY (local outcomes record).
Zeposia is a named product in BMY's portfolio per the Q2 2026 earnings 8-K analysis, and BMY as a whole is in a strong operating stretch, non-GAAP EPS of $2.04 beat the $1.60 consensus by ~27.7% and full-year revenue guidance was raised to $49.0B-$50.0B (local filing analysis).
▼ Bear Case5
No Zeposia-specific catalyst is scheduled in local FDA/event data for the next ~12 months, the approval binary already passed, so there is no dated event for the stock to trade on.
Zeposia is a small part of BMY's portfolio; BMY's near-term FDA catalysts in local data are other drugs (iberdomide PDUFA 2026-08-17, Reblozyl PDUFA 2027-03-11, mezigdomide PDUFA 2027-05-13), and the Q2 2026 analysis credits growth to Opdivo Qvantig, Reblozyl, Camzyos, Breyanzi and Opdualag, not Zeposia.
Analyst positioning is lukewarm: consensus recommendation is 'hold' (8 buy, 6 strong buy, 19 hold, 2 sell) with a mean price target of $64.91 vs. a $65.31 share price, roughly flat implied upside (local analyst data).
Short interest in BMY has been rising: ~44.9M shares short at the 2026-07-15 settlement, +10.87% vs. the prior settlement, ~2.2% of estimated shares outstanding, 4.24 days to cover (local FINRA short-positions data).
BMY's legacy portfolio is eroding (Revlimid -49%, Pomalyst/Imnovid -71% YoY in Q2 2026 per local filing analysis), and Zeposia faces an uncertain competitive position that I could not re-verify on the web this session.

Upcoming Catalysts

  • None specific to Zeposia in local data for the next ~12 months.
  • BMY-level dated catalysts from local FDA data: iberdomide PDUFA 2026-08-17 (relapsed/refractory multiple myeloma); Reblozyl PDUFA 2027-03-11 (myelofibrosis-associated anemia); mezigdomide PDUFA 2027-05-13 (RRMM).
  • BMY quarterly results (next 10-Q/8-K), watch the Zeposia revenue line.

Source Filing

The SecBot filing or press-release report that triggered this drug report:

BRISTOL MYERS SQUIBB CO 8-K BMY ·Originating report

Sources · 4

Hover a chip for the title
1 sec.gov2 sec.gov3 sec.gov4 sec.gov